GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » Asset Impairment Charge

LakeShore Biopharma Co (LakeShore Biopharma Co) Asset Impairment Charge : $1.46 Mil (TTM As of Sep. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co Asset Impairment Charge?

LakeShore Biopharma Co's Asset Impairment Charge for the six months ended in Sep. 2023 was $1.46 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2023 was $1.46 Mil.


LakeShore Biopharma Co Asset Impairment Charge Historical Data

The historical data trend for LakeShore Biopharma Co's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co Asset Impairment Charge Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23
Asset Impairment Charge
0.17 0.69 -0.11

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Asset Impairment Charge Get a 7-Day Free Trial 0.45 0.24 - - 1.46

LakeShore Biopharma Co Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.46 Mil.


LakeShore Biopharma Co Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.


LakeShore Biopharma Co (LakeShore Biopharma Co) Business Description

Traded in Other Exchanges
Address
38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.